Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib Biomarkers in Metastatic Renal Cell Carcinoma
NCT00943839Phase 2Completed
- Sponsor
- Centre Antoine Lacassagne
- Start
- Feb 2009
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC), sponsored by Centre Antoine Lacassagne. Primary endpoints: Objective Response Rate at 5 years and Blood Levels of VEGF and IL-8 at 5 years. Started Feb 2009; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00943839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943839.